Your hospital finance team just spent three weeks building a reimbursement model. The spreadsheets are pristine, the formulas verified. But here’s the uncomfortable truth: you’re making multi-million dollar decisions based solely on your own historical data, with absolutely no visibility into whether your assumptions are competitive or if you’re systematically undervaluing your complex cases.
And accessing real patient-level data from peer institutions? That’s 12-18 months of IRB approvals, data use agreements, and legal reviews… assuming you can even get approval.
This is where synthetic aggregated patient-level DRG datasets fundamentally change the equation.
Why Traditional Approaches to DRG Analytics Fall Short
The healthcare analytics industry has a data access problem that’s getting worse, not better. Since HIPAA’s Privacy Rule and subsequent state-level privacy regulations, the walls around patient-level data have grown higher. For good reason—patient privacy is non-negotiable.
But those same protections create massive operational blind spots for healthcare organizations trying to answer fundamental questions:
- Is our Case Mix Index (CMI) appropriate for our patient population, or are we leaving reimbursement on the table?
- How does our length of stay for hip replacement DRGs compare to regional peers?
- What are the actual cost patterns for sepsis cases across similar-sized institutions?
- Which DRGs represent the highest volume and reimbursement opportunity in our market?
Most organizations attempt to answer these questions through one of three flawed approaches. They purchase aggregated summary statistics that lack the granularity for meaningful analysis. They wait months (sometimes years) for limited access to real de-identified data through research agreements. Or they make strategic decisions based purely on internal data, essentially flying blind to market dynamics.
Here’s what actually works: synthetic DRG datasets that preserve the statistical relationships, clinical logic, and operational patterns of real-world healthcare encounters—without containing a single real patient’s information.
What Makes Synthetic DRG Data Different (and Why It Matters)
Let me be clear about what we’re talking about. Synthetic aggregated patient-level DRG data isn’t simplified summary statistics. It’s not de-identified data with some fields removed. It’s artificially generated patient-level records created using advanced machine learning models—specifically, methodologies for generating statistically valid synthetic data—trained on comprehensive real-world claims datasets.
The keyword here is “patient-level.” Each synthetic record represents a complete inpatient encounter with:
- Diagnosis-Related Group (DRG) assignment and weight
- Primary and secondary diagnoses (ICD-10-CM codes)
- Procedures performed (ICD-10-PCS codes)
- Patient demographics (age, sex, geographic region—all synthetic)
- Length of stay and discharge disposition
- Estimated costs and charges
- Payer type and reimbursement category
- Complication and comorbidity indicators
What makes this powerful for healthcare analytics is that the relationships between these variables are preserved. If real-world data shows that patients aged 65+ with diabetes and heart failure typically have 2.3 days longer stays and 18% higher costs for DRG 291 (Heart Failure), the synthetic data will reflect those same statistical patterns.
But—and this is critical—you cannot reverse-engineer these records back to any actual patient. They’re built using techniques validated by HIPAA’s Expert Determination method for de-identification, meeting the legal standard for non-identifiable data while maintaining GDPR compliance requirements for European healthcare data applications.
The DRG Foundation: Why These Classifications Drive Healthcare Economics
Before diving into specific use cases, it’s worth understanding why DRGs are so central to healthcare operations. Diagnosis-Related Groups were developed in the original development of the DRG system at Yale University in the 1970s as a way to classify hospital cases into groups expected to have similar resource use.
Medicare adopted DRGs as the basis for Medicare’s Inpatient Prospective Payment System (IPPS) in 1983, fundamentally changing how hospitals are paid. Instead of reimbursing based on actual costs incurred (which incentivized longer stays and more procedures), hospitals now receive a fixed payment for each DRG, regardless of actual costs.
This means three things for hospital operations:
First, accurate DRG coding directly impacts revenue. A single diagnosis or procedure code can shift a case from DRG 470 (Major Hip and Knee Joint Replacement without MCC) to DRG 469 (with MCC), changing the reimbursement by thousands of dollars.
Second, operational efficiency becomes financially critical. If your average length of stay for a DRG exceeds the national average, you’re absorbing costs above the fixed reimbursement rate.
Third, Case Mix Index as a critical indicator of hospital complexity and resource use becomes your organization’s financial profile. A higher CMI suggests a more complex, resource-intensive patient population, which affects not just Medicare payments but commercial payer negotiations and financial benchmarking.
Critical Use Cases: Who Needs DRG Patient-Level Data and Why
Hospital Finance and Revenue Cycle Management
This is where synthetic DRG datasets deliver the most immediate ROI. Finance teams are constantly trying to answer: “Are we optimizing reimbursement?”
With access to synthetic aggregated DRG data representing hundreds of peer institutions, you can finally benchmark your performance with statistical confidence. You can calculate your Case Mix Index in context—is your 1.42 CMI appropriate for a 400-bed community hospital in the Nordic region, or are you underperforming compared to similar institutions at 1.58?
More importantly, you can identify specific DRG categories where your coding patterns differ from peers. When your DRG 470 (joint replacement) volume is 30% lower than expected, given your orthopedic service line size, that’s a red flag. Either you’re genuinely treating less complex cases, or there’s a documentation and coding opportunity you’re missing.
Revenue cycle directors use this data to model payer contract negotiations. What happens to your projected revenue if you renegotiate cardiovascular DRG rates upward by 8%? With patient-level synthetic data, you can model the financial impact across your actual case mix distribution, not just average rates.
The operational side is equally valuable. When your length of stay for sepsis DRGs averages 7.2 days while regional peers average 5.8 days, that’s $4,000+ in unreimbursed costs per case. Scale that across 500 annual sepsis admissions, and you’re looking at $2M in operational inefficiency. Synthetic DRG datasets provide the benchmark data to identify and quantify these opportunities.
Healthcare Consultants and Advisory Firms
If you’re building benchmarking reports, due diligence analyses, or strategic recommendations for hospital clients, you know the challenge: your insights are only as good as your comparison data.
Historically, consultants relied on either proprietary databases (expensive, often limited in scope) or publicly available CMS data (free, but highly aggregated and lacking clinical detail). Synthetic DRG patient-level data bridges this gap by providing the granularity of claims data with the accessibility of a commercial dataset.
The power is in the queries you can run. A client asks: “Should we expand our cardiac catheterization lab?” With synthetic DRG data, you can analyze:
- Current market volume for cardiac DRGs by geographic region and facility type
- Average reimbursement and cost patterns for similar procedures
- Patient demographics and comorbidity profiles that drive case complexity
- Seasonal utilization patterns and capacity constraints
- Competitive positioning relative to peer institutions
All of this without waiting 6 months for a data use agreement with a regional health information exchange.
For M&A due diligence, synthetic datasets enable rapid financial profiling. When evaluating a potential hospital acquisition, you can model their reported DRG mix against regional norms, validate their stated CMI, and identify potential revenue optimization opportunities—all before the letter of intent.
This is also where the role of benchmarking in improving healthcare quality and efficiency becomes tangible. Your recommendations move from “based on our experience” to “based on analysis of 250,000 similar patient encounters.”
Health Technology and Algorithm Development
Here’s a problem every health tech startup faces: you need realistic patient data to train and validate your algorithms, but you can’t access real patient data until you sign enterprise customers… who won’t sign until you prove your algorithms work.
Synthetic DRG datasets break this catch-22.
If you’re building a readmission risk prediction model, you need training data with the full range of patient characteristics, diagnoses, procedures, and outcomes. Traditional approaches involve partnerships with health systems (slow, legally complex) or using publicly available datasets like MIMIC-III (limited scope, heavily utilized by competitors, and still requires IRB approval in many contexts).
Synthetic patient-level data provides a third path. You get statistically valid training data that reflects real-world clinical complexity and operational patterns, but without the privacy constraints of real patient records. You can share this data with your development team, overseas contractors, and cloud-based ML pipelines without triggering HIPAA business associate agreements or GDPR data processing concerns.
The applications extend beyond predictive modeling. Revenue cycle management software needs realistic test data to validate denial prediction logic. Clinical decision support tools need diverse patient scenarios to ensure recommendations work across demographic and clinical populations. Population health platforms need realistic utilization patterns to test their risk stratification algorithms.
In every case, synthetic DRG data provides a safe, realistic testing environment that accelerates development while maintaining compliance.
Life Sciences and Market Access Strategy
Pharmaceutical and medical device companies increasingly rely on FDA framework for Real-World Evidence to demonstrate value and secure reimbursement. But generating that evidence requires access to real-world data that’s both comprehensive and defensible.
Synthetic DRG datasets enable health economics and outcomes research (HEOR) teams to model disease burden, treatment pathways, and economic impact without the multi-year process of negotiating access to payer claims data.
Consider a company launching a novel heart failure therapy. The market access team needs to answer: What’s the current cost and resource utilization for heart failure admissions? What’s the length of stay distribution? What comorbidities are most common, and how do they impact costs? What’s the readmission rate, and how does it vary by patient characteristics?
With synthetic DRG data covering heart failure admissions (DRG 291-293), you can build a comprehensive economic model showing the current standard-of-care costs, identify high-cost patient subgroups most likely to benefit from your therapy, and project the budget impact of formulary inclusion—all with data that statistically mirrors real-world patterns but carries zero patient privacy risk.
This extends to competitive intelligence and market sizing. Which institutions are high-volume prescribers for certain therapy categories? What’s the geographic distribution of target patient populations? How has DRG utilization trended over the past 3-5 years? Synthetic datasets built from recent claims data can answer these questions with far more precision than traditional market research.
For medical device companies, the applications are similar but often more operationally focused. Understanding procedural volumes, device utilization patterns, and cost-effectiveness across different hospital types and regions informs everything from pricing strategy to sales territory planning.
Dataset Components: What You’re Actually Getting
The value of a synthetic DRG dataset depends entirely on its comprehensiveness and clinical validity. Here’s what should be included in any analysis-ready DRG dataset:
Core DRG Classification and Grouping
Every record should include the assigned DRG code and corresponding DRG weight based on current CMS classifications. For international applications, datasets should also include country-specific groupings—for example, Continental European DRG systems for hospital reimbursement differ significantly from the U.S. MS-DRG structure, with variations across Switzerland, Austria, and Nordic countries.
The DRG weight is particularly critical because it directly drives reimbursement calculations. A DRG weight of 1.5 means that case is expected to cost 1.5 times the national average, affecting both the payment rate and the hospital’s overall CMI calculation.
Diagnosis and Procedure Coding
Patient-level records should include the full hierarchy of diagnosis codes (principal diagnosis plus secondary diagnoses) using ICD-10-CM classification, and all procedures performed using ICD-10-PCS codes. This level of detail is essential for understanding case complexity and validating DRG assignment logic.
The distinction between Major Complication/Comorbidity (MCC), Complication/Comorbidity (CC), and non-CC diagnoses is particularly important, as these modifiers often determine the DRG assignment and subsequent reimbursement differential.
Patient Demographics and Clinical Characteristics
Synthetic patient records include age, sex, race/ethnicity categories, and geographic location (typically at the regional level). All of these are artificially generated—no real patient’s demographic information is included.
What matters is that the distributions and correlations match real-world patterns. If 68% of heart failure patients are over age 65 in real claims data, the synthetic data should reflect that same proportion. If diabetes prevalence is higher in certain geographic regions, those regional differences should be preserved.
Utilization and Resource Metrics
This is where DRG data becomes operationally actionable. Each synthetic record should include length of stay, ICU days (if applicable), discharge disposition (home, skilled nursing facility, transfer, etc.), and estimated costs and charges.
Cost data is particularly valuable but also complex. Because actual cost accounting varies dramatically across hospitals, synthetic datasets typically include the application of DRG and cost-groupers in health economic modeling that normalize costs using industry-standard cost-to-charge ratios or relative value units.
Payer and Reimbursement Information
Records include payer type (Medicare, Medicaid, commercial insurance, self-pay) and estimated reimbursement based on DRG rates. This enables financial modeling and payer mix analysis without requiring actual contracted rates, which are proprietary and commercially sensitive.
Quality and Outcomes Indicators
Advanced synthetic datasets include mortality indicators, readmission flags (30-day readmission for specific conditions), and hospital-acquired condition markers. These outcome measures are critical for quality benchmarking and risk-adjusted performance comparisons.
Navigating the Data Landscape: Key Considerations in Source Selection
The challenge many pharmaceutical companies and healthcare organizations face isn’t finding synthetic data providers—it’s determining which combination of capabilities, coverage characteristics, and analytical features aligns with their strategic priorities.
Understanding the key dimensions of variation across available options requires careful evaluation of both your use cases and the broader market landscape.
Coverage and Geographic Scope
Healthcare is intensely local. A cardiovascular service line strategy that works in Houston might fail in rural Montana. DRG utilization patterns in Switzerland differ fundamentally from those in the United States or the Nordic countries.
Coverage breadth varies dramatically across providers. Some maintain longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types, while others focus on specific geographies or populations with greater clinical depth. The right choice depends on whether your questions require national representativeness or regional precision.
For international markets, the requirements become even more specific. Pan-European applications require understanding diverse classification systems—Swiss DRG systems, Austrian LKF groupings, and Nordic NordDRG classifications each have different grouping logic and reimbursement structures. Datasets should include regional granularity, hospital ownership type (public, private, non-profit), and integration with local pharmacy and ambulatory care codes.
The value of this geographic specificity shows up immediately in market analysis. If you’re a MedTech company planning a cardiac device launch, you need to know not just national DRG volumes but regional concentration. Are cardiovascular procedures concentrated in major academic medical centers, or is there substantial volume in community hospitals? That answer varies dramatically by country and region, and it fundamentally shapes your go-to-market strategy.
Analytical Sophistication and Tool Integration
Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. The choice depends on whether you need descriptive intelligence (what happened) or forward-looking insights (what’s likely to happen).
Some sources provide raw data files requiring significant data engineering before analysis can begin. Others offer fully integrated analytical platforms with pre-built queries, visualization tools, and predictive models. The gap between licensing data and extracting actionable intelligence can be substantial—understanding where your organization falls on the self-service versus full-service spectrum is critical.
Data Integration and Complementary Sources
Some synthetic datasets combine DRG records with complementary data sources—lab results, specialty pharmacy utilization, provider characteristics, social determinants of health—for richer patient profiles. This vertical integration creates analytical possibilities that pure DRG data cannot support, such as understanding the relationship between lab values and length of stay, or analyzing how social factors impact readmission risk.
The decision about whether you need this integration depends on your analytical objectives. For straightforward benchmarking and financial modeling, core DRG data may suffice. For complex HEOR studies or predictive algorithm development, integrated datasets become essential.
Data Recency and Update Frequency
Timing matters in healthcare analytics. Some providers offer near-real-time data updated monthly or quarterly, enabling analysis of current trends and seasonal patterns. Others focus on fully adjudicated historical data with longer lag times but greater billing accuracy.
For commercial forecasting and competitive intelligence, recency is often paramount. For regulatory submissions and retrospective research, adjudicated accuracy may matter more than timeliness. Understanding this trade-off helps identify the right data characteristics for your applications.
Cost Models and Licensing Structures
Pricing varies enormously across the market, from per-query models to unlimited-use licenses, from therapeutic-area-specific subsets to comprehensive databases. Some providers charge based on data volume extracted, others on number of users or analytical questions asked.
Understanding total cost of ownership requires looking beyond initial licensing fees to consider data engineering costs, analytical tool expenses, and ongoing update fees. The “cheapest” option often becomes expensive once hidden costs emerge.
Leveraging Expert Guidance for Strategic Data Decisions
Navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem. The gap between understanding what synthetic DRG data can do theoretically and identifying which specific capabilities, coverage patterns, and cost structures match your needs is substantial.
Most companies overlook critical considerations during initial evaluations—therapeutic area depth, longitudinal tracking capabilities, geographic granularity in key markets, and compatibility with existing analytical infrastructure. These oversights lead to expensive mismatches discovered months into licensing agreements.
Expert advisors who understand both your business objectives and the data landscape can accelerate your path to value while avoiding common pitfalls. They bring market knowledge about which combinations of data characteristics typically support specific use cases, negotiation experience to optimize licensing terms, and implementation expertise to ensure smooth integration with your analytical workflows.
Addressing the Skepticism: Can Synthetic Data Really Be Trusted?
If you’re reading this thinking “this sounds too good to be true,” that’s a healthy skepticism. The medical research community has been burned before by datasets that looked comprehensive but contained systematic biases or lacked clinical validity.
So let’s address the core concern directly: How do you know synthetic DRG data accurately reflects real-world patterns?
The answer comes down to three validation steps that any reputable synthetic data provider should demonstrate:
First: Statistical Fidelity Testing. The synthetic dataset should be compared against the source real-world data across hundreds of statistical measures. This includes univariate distributions (does the age distribution match?), bivariate correlations (does the relationship between diabetes and length of stay match?), and multivariate patterns (does the clustering of high-cost, high-complexity cases match?).
Academic research on successful applications of synthetic data in health services research has established benchmarks for acceptable fidelity. Quality synthetic data should preserve 95%+ of the statistical properties of the source data.
Second: Clinical Plausibility Review. Statistical fidelity isn’t enough—the data also needs to make clinical sense. A synthetic patient record showing a 28-year-old with a hip fracture DRG, 8 comorbidities, and a 2-day length of stay would be statistically possible but clinically implausible.
This is where the validity of administrative claims data for outcomes and health services research becomes relevant. Reputable synthetic data goes through clinical review panels that validate the plausibility of diagnosis-procedure combinations, length of stay patterns, and cost relationships.
Third: Privacy Risk Assessment. The entire point of synthetic data is privacy protection, which means rigorous testing for re-identification risk. This typically involves attempting to match synthetic records back to the source real data using various combinations of quasi-identifiers (age, sex, diagnoses, procedures, geography).
If successful matching rates exceed random chance, that indicates privacy risk. Quality synthetic data should demonstrate that re-identification attempts perform no better than random guessing, meeting the standard for HIPAA’s Expert Determination method and GDPR compliance requirements for data anonymization.
What synthetic data is not appropriate for: Individual patient care decisions, regulatory reporting that requires verified real patient data, or any application where the legal or clinical requirement is specifically for non-synthetic data. Synthetic data is for analysis, research, and decision support—not for direct patient care.
Practical Implementation: From Data Access to Actionable Insights
The measure of any dataset is time-to-insight. How quickly can you go from data access to answering your strategic questions?
With traditional real-world data access, that timeline is measured in months: 3-6 months for legal approvals and data use agreements, 2-4 weeks for data transfer and initial quality checks, 4-8 weeks for data engineering and normalization, and only then can you begin actual analysis.
Analysis-ready synthetic DRG datasets compress this timeline dramatically. Because the data is pre-structured, validated, and mapped to standard code sets, you move from licensing to first query in days, not months.
Define Requirements Before Evaluating Options
The most successful implementations begin with clarity about what questions you need answered. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters.
This requirements definition prevents costly mismatches where you discover six months into a licensing agreement that the data lacks critical therapeutic depth or geographic granularity for your key use cases. Expert consultants can help structure this requirements process to ensure you’re comparing options on the dimensions that actually matter.
Common Analytical Workflows
For benchmarking applications, the workflow typically involves: defining your comparison cohort (similar hospital size, region, teaching status), filtering the synthetic dataset to matching criteria, calculating key metrics (CMI, length of stay, cost per case, complication rates) for both your institution and the benchmark cohort, and identifying statistically significant variances that represent opportunities.
For market sizing and forecasting, the approach involves: identifying relevant DRGs for your product or service, analyzing historical volume trends and seasonal patterns, segmenting the market by geography, payer mix, and patient demographics, and building projection models based on population health trends and regulatory changes.
For algorithm development and validation, the process includes: sampling the synthetic dataset to create training, validation, and test sets, ensuring appropriate class balance and representation, training your model on the synthetic data, and validating performance metrics before deployment on real client data.
Pilot Before Scaling
Start with a focused project to validate that your chosen data source and analytical approach actually answer your questions before committing to large-scale licensing agreements. This pilot phase should test not just data quality but also your team’s ability to extract insights efficiently with the available tools and support.
Your Next Steps with MEDDDICAL
Whether you’re optimizing hospital revenue cycle operations, building market access strategies for a pharmaceutical launch, or developing the next generation of healthcare analytics tools, access to comprehensive, privacy-safe DRG data changes what’s possible.
But understanding what types of synthetic DRG data exist and what questions they can answer is just the first step. The second step—matching your requirements to the right combination of data coverage, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem.
MEDDDICAL specializes in helping pharmaceutical and healthcare organizations navigate the complex landscape of real-world data sources. We provide strategic advisory services to help you:
- Define your data requirements based on your specific analytical objectives
- Understand the key dimensions of variation across synthetic data providers
- Evaluate which combinations of coverage, capabilities, and cost structures align with your use cases
- Avoid common pitfalls that lead to expensive mismatches between needs and solutions
- Accelerate your path from data licensing to actionable insights
Contact us to discuss your specific data requirements and explore strategic approaches to real-world intelligence that align with your business objectives. Our expertise in both the pharmaceutical industry and the data vendor landscape helps you make informed decisions that deliver value while avoiding costly mistakes.
Frequently Asked Questions About DRG Datasets
What’s the difference between synthetic and de-identified patient data?
De-identified data starts with real patient records and removes direct identifiers like names and medical record numbers. However, it still carries re-identification risk because the underlying record represents an actual person’s healthcare encounter. Synthetic data is artificially generated—no record corresponds to any real patient—but preserves the statistical patterns and clinical relationships found in real-world data. This makes synthetic data legally and ethically different, with virtually zero re-identification risk while meeting GDPR requirements for data anonymization.
Can I use synthetic DRG data for regulatory submissions?
It depends on the submission requirements. Synthetic data is increasingly accepted for economic modeling, budget impact analyses, and market research that supports regulatory submissions. However, if the regulatory body specifically requires verified real-world patient data (such as for post-market surveillance reporting), synthetic data would not be appropriate. For FDA submissions incorporating Real-World Evidence, consult with regulatory affairs specialists on whether synthetic data meets the specific evidence requirements.
How current is the synthetic data?
Quality synthetic datasets should be generated from recent source data, typically refreshed annually or semi-annually to reflect current clinical practices, coding guidelines, and reimbursement structures. Because DRG classifications and weights change each federal fiscal year, it’s essential that synthetic data reflects the most current grouping logic. Always verify the data vintage and ensure it aligns with your analysis timeframe.
What’s the coverage and sample size?
Comprehensive synthetic DRG datasets should represent millions of inpatient encounters across diverse hospital types, geographic regions, and patient populations. The specific sample size depends on your analytical needs—market-level analyses might require 1M+ records for statistical confidence, while focused clinical studies might work with 50K-100K records in specific DRG categories. More important than absolute size is representativeness: does the dataset reflect the diversity of your target population?
How do I validate that synthetic data is accurate for my use case?
Start by requesting sample data for a limited scope (specific DRGs, geographic region, or time period) and running basic validation queries. Compare aggregate statistics—DRG volume rankings, average length of stay, CMI distributions—against publicly available benchmarks like CMS data. If the synthetic data closely matches known real-world patterns for these aggregate measures, that’s a strong indicator of overall fidelity. For critical applications, consider engaging an independent statistician to perform more rigorous validation testing.
Sources and References
- Fetter, R.B., et al. (1980). “Case mix definition by diagnosis-related groups.” Medical Care, 18(2 Suppl):1-53. Available at: https://pubmed.ncbi.nlm.nih.gov/6122407/
- Centers for Medicare & Medicaid Services. (2024). “Acute Inpatient Prospective Payment System.” Available at: https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps
- Averill, R.F., et al. (2013). “The evolution of case mix measurement using diagnosis related groups (DRGs).” Health Affairs. Available at: https://www.healthaffairs.org/doi/10.1377/hlthaff.2013.0133
- U.S. Department of Health and Human Services. (2012). “Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with HIPAA Privacy Rule.” Available at: https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html
- Hernandez, M., et al. (2023). “A methodological guide for generating synthetic data using statistical and machine learning techniques.” Nature Scientific Data, 10:176. Available at: https://www.nature.com/articles/s41597-023-02166-2
- Chen, J., et al. (2021). “Synthetic health data generation and evaluation: A methodological review.” Journal of Biomedical Informatics. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378608/
- Iezzoni, L.I. (2005). “Validating administrative data in health services research.” Medical Care, 43(10):II-61–II-64. Available at: https://journals.lww.com/lww-medicalcare/Abstract/2005/10000/Validating_Administrative_Data_in_Health_Services.13.aspx
- U.S. Food and Drug Administration. (2018). “Framework for FDA’s Real-World Evidence Program.” Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- Institut für das Entgeltsystem im Krankenhaus (InEK). (2024). “G-DRG System 2024.” Available at: https://www.g-drg.de/cms/G-DRG-System_2024
- The Commonwealth Fund. (2021). “The Role of Benchmarking in Improving Health Care Quality and Efficiency.” Available at: https://www.commonwealthfund.org/publications/fund-reports/2021/aug/role-benchmarking-improving-health-care-quality
- Kirson, N., et al. (2018). “The application of DRGs and cost-groupers in health economic modeling.” The European Journal of Health Economics, 19:993–1005. Available at: https://link.springer.com/article/10.1007/s10198-018-0992-8